These non-promotional scientific presentations were presented at the medical congresses referenced below and are intended for U.S healthcare professionals who were in attendance for the purposes of scientific exchange.
These materials may contain information outside of the FDA approved label or relate to uses that have not been approved by the FDA. Syndax does not recommend use of Syndax products in any manner other than as described in the FDA-approved Prescribing Information.
European Hematology Association Annual Congress 2026
Results 12
Poster Presentation | Jun 13, 2026
A phase 1/2 study of the menin inhibitor revumenib with the CELMod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias
View MaterialPoster Presentation | Jun 13, 2026
Revumenib as maintenance for AML following allogeneic stem cell transplantation
View MaterialPoster Presentation | Jun 13, 2026
Clinical activity of revumenib in patients with relapsed/refractory NUP98-rearranged acute leukemias
View MaterialPoster Presentation | Jun 13, 2026
Revumenib therapy post hematopoietic stem cell transplant for patients with relapsed/refractory KMT2Ar, NPM1m, and NUP98r acute myeloid leukemia: post hoc analysis of outcomes from AUGMENT-101
View MaterialPoster Presentation | Jun 12, 2026
Revumenib + intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated phase 1 results from SNDX-5613-0708
View MaterialPoster Presentation | Jun 12, 2026
Efficacy of revumenib in acute myeloid leukemia harboring NPM1-mutated co-mutations: post hoc analysis of AUGMENT-101
View MaterialPoster Presentation | Jun 12, 2026
Pharmacokinetic assessment of revumenib in patients with relapsed/refractory acute leukemias harboring a KMT2A rearrangement or NPM1 mutation: Impact of food and concomitant medications
View MaterialPoster Presentation | Jun 12, 2026
Phase 1/2 study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in relapsed/refractory AML
View MaterialPoster Presentation | Jun 12, 2026